Meeting
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
Authors
Susan M. Dombrowski
Exact Sciences, Phoenix, AZ
Susan M. Dombrowski , Sameer S. Udhane , Gargi D. Basu , David W. Hall , Jess W. Hoag , Fadel S. Alyaqoub , Pawan Noel , Szabolcs Szelinger , Min Wang , Audrey A. Ozols , Janine R. LoBello , Snehal Govind Thakkar , Frederick L. Baehner , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1096)
DOI
10.1200/JCO.2022.40.16_suppl.1096
Abstract #
1096
Poster Bd #
473
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comprehensive genomic profiling to identify gene alterations in DNA repair pathway across solid tumors.
First Author: Kevin McDonnell
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George